• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by BriaCell Therapeutics Corp.

    8/1/22 7:00:12 AM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BCTX alert in real time by email
    SC 13G 1 tm2222010d1_sc13g.htm SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

      

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. ____)*

      

    BriaCell Therapeutics Corp.

    (Name of Issuer)

     

    Common Stock, no par value

    (Title of Class of Securities)

     

    10778Y302

    (CUSIP Number)

     

    July 20, 2022

    (Date of Event Which Requires Filing of this Statement)

      

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)

     

    xRule 13d-1(c)

     

    ¨Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

      

     

     Page 1 of 10 Pages 

     

     

    CUSIP No. 10778Y302

     

    1.Names of Reporting Persons

     

    Lynwood Opportunities Master Fund

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a)¨
    (b)¨

     

    3.SEC Use Only

     

    4.Citizenship or Place of Organization

     

    Cayman Islands

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: 5.  SOLE VOTING POWER 870,000
    6.  SHARED VOTING POWER 0
    7.  SOLE DISPOSITIVE POWER

    870,000

    8.  SHARED DISPOSITIVE POWER 0

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person

     

    870,000

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)   ¨

     

    11.Percent of Class Represented by Amount in Row (9)

     

    5.6%

     

    12.Type of Reporting Person (See Instructions)

     

    OO

     

     

     

    *            The information above is given as of the end of business on July 29, 2022, the business day before the filing date of this Schedule 13G.

     

     Page 2 of 10 Pages 

     

     

     

    CUSIP No. 10778Y302

     

    1.Names of Reporting Persons

     

    Lynwood Capital Management Inc.

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a)¨
    (b)¨

     

    3.SEC Use Only

     

    4.Citizenship or Place of Organization

     

    Ontario, Canada

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: 5.  SOLE VOTING POWER 870,000
    6.  SHARED VOTING POWER 0
    7.  SOLE DISPOSITIVE POWER 870,000
    8.  SHARED DISPOSITIVE POWER 0

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person

     

    870,000

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.Percent of Class Represented by Amount in Row (9)

     

    5.6%

     

    12.Type of Reporting Person (See Instructions)

     

    CO

     

     

     

    *            The information above is given as of the end of business on July 29, 2022, the business day before the filing date of this Schedule 13G.

     

     Page 3 of 10 Pages 

     

      

    CUSIP No. 10778Y302

     

    1.Names of Reporting Persons

     

    Ben Shapiro

     

    2.Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a)¨
    (b)¨

     

    3.SEC Use Only

     

    4.Citizenship or Place of Organization

     

    Canada

     

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH: 5.  SOLE VOTING POWER 870,000
    6.  SHARED VOTING POWER 0
    7.  SOLE DISPOSITIVE POWER 870,000
    8.  SHARED DISPOSITIVE POWER 0

     

    9.Aggregate Amount Beneficially Owned by Each Reporting Person

     

    870,000

     

    10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨

     

    11.Percent of Class Represented by Amount in Row (9)

     

    5.6%

     

    12.Type of Reporting Person (See Instructions)

     

    IN

     

     

     

    *            The information above is given as of the end of business on July 29, 2022, the business day before the filing date of this Schedule 13G.

     

     Page 4 of 10 Pages 

     

     

    Item 1.

     

    (a)The name of the issuer is BriaCell Therapeutics Corp. (the “Issuer”).

     

    (b)The principal executive offices of the Issuer are located at Suite 300, 235 15th Street, West Vancouver, British Columbia, V7T 2X1.

     

    Item 2.

     

    (a)This Schedule 13G (this “Statement” or this “Schedule 13G”) is being filed by: (1) Lynwood Opportunities Master Fund, a Cayman Islands entity (the “Fund”); (2) Lynwood Capital Management Inc., an Ontario corporation (the “Investment Manager”); and (3) Ben Shapiro (“Mr. Shapiro”) (all of the foregoing, collectively, the “Reporting Persons”). The Fund is an investment vehicle. The Fund directly beneficially owns the Common Stock (as defined below) reported in this Statement. The Investment Manager is the investment manager of the Fund. Mr. Shapiro is the President, Chief Executive Officer, Chief Investment Officer, sole director and indirect controlling stockholder of the Investment Manager. Mr. Shapiro and the Investment Manager may be deemed to beneficially own the Common Stock directly beneficially owned by the Fund. Each Reporting Person disclaims beneficial ownership with respect to any Common Stock other than the shares directly beneficially owned by such Reporting Person.

     

    (b)

    The principal business office of the Fund is FG Services Limited, Suite 2206, Cassia Court, 72 Market Street, Camana Bay, P.O. Box 30869, Grand Cayman KY1-1204, Cayman Islands. The principal business office of the Investment Manager and Mr. Shapiro is 200 Bay St, Suite 1304, Royal Bank Plaza, South Tower, Toronto, Ontario M5J 2J1.

     

    (c)For citizenship information see Item 4 of the cover page of each Reporting Person.

     

    (d)

    This Statement relates to the Common Stock, no par value, of the Issuer (the “Common Stock”).

     

    (e)The CUSIP Number of the Common Stock is 10778Y302.

     

    Item 3. If this statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
    (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e) ¨ An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E);
    (f) ¨ An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F);
    (g) ¨ A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G);
    (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
    (k) ¨ Group, in accordance with §240.13d-1(b)(1)(ii)(K).

     

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: ______________

     

     Page 5 of 10 Pages 

     

     

    Item 4. Ownership.

     

    See Items 5-9 and 11 on the cover page for each Reporting Person, and Item 2, which information is given as of the end of business on July 29, 2022, the business day before the date of filing of this Schedule 13G.

     

    As of the Event Date of July 20, 2022, the Fund owned 796,200 shares of Common Stock, representing 5.1% of the Common Stock outstanding.

     

    The percentages of beneficial ownership contained herein are based on 15.5 million shares of Common Stock outstanding as of June 28, 2022, as reported by the Issuer in an Investor Presentation accessed from the Issuer’s website.

     

    Item 5. Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ¨

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

     Page 6 of 10 Pages 

     

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10. Certification.

     

    (a)Not applicable.

     

    (b)Not applicable.

     

    (c)By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

     

     Page 7 of 10 Pages 

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: August 1, 2022

     

    Lynwood Opportunities Master Fund

    Lynwood Capital Management Inc.

    Ben Shapiro

     

    By: /s/ Ben Shapiro  
      Ben Shapiro, for himself, and as President, Chief Executive Officer and Chief Investment Officer of the Investment Manager (for itself and on behalf of the Fund)  

     

     

     Page 8 of 10 Pages 

     

     

    EXHIBIT INDEX

     

     

    Exhibit No. Document
       
        1 Joint Filing Agreement

     

     Page 9 of 10 Pages 

    Get the next $BCTX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BCTX

    DatePrice TargetRatingAnalyst
    2/14/2022$25.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $BCTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BriaCell Selected for MSK's 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer

    PHILADELPHIA and VANCOUVER, British Columbia, Aug. 13, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ)), (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce its acceptance into Memorial Sloan Kettering Cancer Center's (MSK's) Therapeutics Accelerator 2025 Cohort program. This project aims to accelerate the clinical development of Bria-OTS+, BriaCell's next generation personalized off-the-shelf immunotherapy, for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. As one of the world's foremost canc

    8/13/25 7:30:30 AM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BriaCell Announces Proposed Effective Date of Share Consolidation

    PHILADELPHIA and VANCOUVER, British Columbia, Aug. 05, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care announced today that the Company's board of directors has approved the consolidation (the "Consolidation") of the Company's issued and outstanding common shares (the "Common Shares") on the basis of one (1) post-Consolidation Common Share for every ten (10) pre-Consolidation Common Shares. The Consolidation is being implemented to ensure that the Company continues to comply with the listing requirements of The Nasdaq

    8/5/25 8:17:16 PM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study

    PHILADELPHIA and VANCOUVER, British Columbia, July 31, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW, BCTXZ)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, announces the addition of UCLA Health Jonsson Comprehensive Cancer Center, a leading cancer center in California, to its ongoing pivotal Phase 3 clinical study (Bria-ABC, NCT06072612) evaluating Bria-IMT™ in combination with a checkpoint inhibitor versus physician's choice in patients with advanced metastatic breast cancer (MBC). "The randomized Phase 2 data reported with the Bria-IMT combination regimen are encoura

    7/31/25 7:30:13 AM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCTX
    SEC Filings

    View All

    SEC Form S-8 filed by BriaCell Therapeutics Corp.

    S-8 - BriaCell Therapeutics Corp. (0001610820) (Filer)

    7/31/25 7:01:41 PM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by BriaCell Therapeutics Corp.

    SCHEDULE 13G - BriaCell Therapeutics Corp. (0001610820) (Subject)

    7/28/25 11:38:34 AM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BriaCell Therapeutics Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - BriaCell Therapeutics Corp. (0001610820) (Filer)

    7/16/25 4:15:57 PM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Lustig Marc bought $2,000,001 worth of shares (902,935 units at $2.21) (SEC Form 4)

    4 - BriaCell Therapeutics Corp. (0001610820) (Issuer)

    5/20/24 4:00:14 PM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: Bondarenko Jamieson bought $128,240 worth of shares (28,000 units at $4.58), increasing direct ownership by 20% to 169,856 units

    4 - BriaCell Therapeutics Corp. (0001610820) (Issuer)

    12/28/22 4:38:08 PM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Williams William V.

    4 - BriaCell Therapeutics Corp. (0001610820) (Issuer)

    12/28/22 3:22:52 PM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. initiated coverage on BriaCell Therapeutics with a new price target

    HC Wainwright & Co. initiated coverage of BriaCell Therapeutics with a rating of Buy and set a new price target of $25.00

    2/14/22 6:04:45 AM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Lustig Marc bought $2,000,001 worth of shares (902,935 units at $2.21) (SEC Form 4)

    4 - BriaCell Therapeutics Corp. (0001610820) (Issuer)

    5/20/24 4:00:14 PM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCTX
    Leadership Updates

    Live Leadership Updates

    View All

    BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

    PHILADELPHIA, Pa. and VANCOUVER, British Columbia, Feb. 05, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce the results of its annual general meeting of shareholders of the Company (the "Shareholders") for the year ended July 31, 2024 held on February 5, 2025 (the "Meeting"). A total of 36.26% of the Company's issued and outstanding common shares (the "Common Shares") were voted at the Meeting. At the Meeting, the Shareholders overwhelmingly voted in favour of all proposed resolutions, consisting of

    2/5/25 6:15:47 PM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BriaCell Announces Rescheduling of its Annual General Meeting of Shareholders to February 5, 2025

    PHILADELPHIA and VANCOUVER, British Columbia, Jan. 03, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that the Company's Annual General Meeting of Shareholders (the "Meeting"), which was originally scheduled to be held on Thursday, January 23, 2025, has been rescheduled. The Meeting is now scheduled to be held on Wednesday, February 5, 2025, at 9:00 a.m. (ET) at Suite 3400, One First Canadian Place, Toronto, ON, M5X 1A4. The record date for the Meeting, December 9, 2024, is unchanged and applies to the postponed

    1/3/25 5:05:00 PM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BriaCell Announces Availability of Annual General Meeting Materials and Alternative Voting Procedures

    PHILADELPHIA and VANCOUVER, British Columbia, Dec. 17, 2024 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces that the Company will be relying on, and has satisfied all of the conditions to rely on, CSA Coordinated Blanket Order 51-931 for exemption from the requirements to send proxy-related materials (the "Meeting Materials") for its upcoming annual general meeting (the "Meeting") to be held on Thursday, January 23, 2025, at Suite 3400, One First Canadian Place, Toronto, ON, M5X 1A4. at 10:00 a.m. (EST) due to the susp

    12/17/24 4:05:59 PM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by BriaCell Therapeutics Corp.

    SC 13D/A - BriaCell Therapeutics Corp. (0001610820) (Subject)

    12/12/24 6:06:07 AM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by BriaCell Therapeutics Corp.

    SC 13D/A - BriaCell Therapeutics Corp. (0001610820) (Subject)

    12/10/24 6:06:45 AM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by BriaCell Therapeutics Corp.

    SC 13D/A - BriaCell Therapeutics Corp. (0001610820) (Subject)

    12/5/24 7:45:06 AM ET
    $BCTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BCTX
    Financials

    Live finance-specific insights

    View All

    ImmunoPrecise Reports Financial Results and Recent Business Highlights for Full Fiscal Year 2023

    The Company achieved revenue of $20.7 million during the year ended April 30, 2023, a 6.7% increase from the year ended April 30, 2022. YoY growth increases to 9.0% when adjusting for the effects of currency translation. The Company recorded total revenue of $5.6 million during the three months ended April 30, 2023, the highest quarterly revenue total the Company has recorded. IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ:IPA), an AI-driven biotherapeutic research and technology company, today announced financial results for the full fiscal year 2023 ended April 30, 2023. "As we usher in Fiscal Year 2024, we carry with us a strong momentum from the impressive

    7/7/23 8:10:00 AM ET
    $BCTX
    $IPA
    Biotechnology: Pharmaceutical Preparations
    Health Care